The influence of diabetes on cardiac beta-adrenoceptor subtypes. 2007

V Melih Altan, and Ebru Arioglu, and Sahika Guner, and A Tanju Ozcelikay
Department of Pharmacology, Faculty of Pharmacy, University of Ankara, Tandogan, Ankara, 06100, Turkey. maltan@pharmacy.ankara.edu.tr

Despite the significant developments in the treatment of diabetes mellitus, diabetic patients still continue to suffer from cardiac complications. The increase of cardiac adrenergic drive may ultimately contribute to the development and progression of diabetic cardiomyopathy. beta-Adrenoceptors play an important role in the regulation of heart function. However, responsiveness of diabetic heart to beta-adrenoceptor agonist stimulation is diminished. The chronotropic responses mediated by beta(1)-subtype, which is mainly responsible for cardiac effects of catecholamines are decreased in the atria of diabetic rats. The expression of cardiac beta(1)-subtype is significantly decreased in diabetic rats as well. beta(2)-Adrenoceptors also increase cardiac function. Although the expression of this subtype is slightly decreased in diabetic rat hearts, beta(2)-mediated chronotropic responses are preserved. On the other hand, functional beta(3)-adrenoceptor subtype was characterized in human heart. Interestingly, stimulation of cardiac beta(3)-adrenoceptors, on the contrary of beta(1)- and beta(2)-subtypes, mediates negative inotropic effect in human ventricular muscle. Cardiac beta(3)-adrenoceptors are upregulated in experimental diabetes as well as in human heart failure. These findings suggest that each beta-adrenoceptor subtype may play an important role in the pathophysiology of diabetes-induced heart disease. However, it is still not known whether the changes in the expression and/or responsiveness of beta-adrenoceptors are adaptive or maladaptive. Therefore, this review outlines the potential roles of these receptor subtypes in cardiac pathologies of diabetes.

UI MeSH Term Description Entries
D009202 Cardiomyopathies A group of diseases in which the dominant feature is the involvement of the CARDIAC MUSCLE itself. Cardiomyopathies are classified according to their predominant pathophysiological features (DILATED CARDIOMYOPATHY; HYPERTROPHIC CARDIOMYOPATHY; RESTRICTIVE CARDIOMYOPATHY) or their etiological/pathological factors (CARDIOMYOPATHY, ALCOHOLIC; ENDOCARDIAL FIBROELASTOSIS). Myocardial Disease,Myocardial Diseases,Myocardial Diseases, Primary,Myocardial Diseases, Secondary,Myocardiopathies,Primary Myocardial Disease,Cardiomyopathies, Primary,Cardiomyopathies, Secondary,Primary Myocardial Diseases,Secondary Myocardial Diseases,Cardiomyopathy,Cardiomyopathy, Primary,Cardiomyopathy, Secondary,Disease, Myocardial,Disease, Primary Myocardial,Disease, Secondary Myocardial,Diseases, Myocardial,Diseases, Primary Myocardial,Diseases, Secondary Myocardial,Myocardial Disease, Primary,Myocardial Disease, Secondary,Myocardiopathy,Primary Cardiomyopathies,Primary Cardiomyopathy,Secondary Cardiomyopathies,Secondary Cardiomyopathy,Secondary Myocardial Disease
D011943 Receptors, Adrenergic, beta One of two major pharmacologically defined classes of adrenergic receptors. The beta adrenergic receptors play an important role in regulating CARDIAC MUSCLE contraction, SMOOTH MUSCLE relaxation, and GLYCOGENOLYSIS. Adrenergic beta-Receptor,Adrenergic beta-Receptors,Receptors, beta-Adrenergic,beta Adrenergic Receptor,beta-Adrenergic Receptor,beta-Adrenergic Receptors,Receptor, Adrenergic, beta,Adrenergic Receptor, beta,Adrenergic beta Receptor,Adrenergic beta Receptors,Receptor, beta Adrenergic,Receptor, beta-Adrenergic,Receptors, beta Adrenergic,beta Adrenergic Receptors,beta-Receptor, Adrenergic,beta-Receptors, Adrenergic
D005786 Gene Expression Regulation Any of the processes by which nuclear, cytoplasmic, or intercellular factors influence the differential control (induction or repression) of gene action at the level of transcription or translation. Gene Action Regulation,Regulation of Gene Expression,Expression Regulation, Gene,Regulation, Gene Action,Regulation, Gene Expression
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D048909 Diabetes Complications Conditions or pathological processes associated with the disease of diabetes mellitus. Due to the impaired control of BLOOD GLUCOSE level in diabetic patients, pathological processes develop in numerous tissues and organs including the EYE, the KIDNEY, the BLOOD VESSELS, and the NERVE TISSUE. Complications of Diabetes Mellitus,Diabetes-Related Complications,Diabetic Complications,Diabetes Complication,Diabetes Mellitus Complication,Diabetes Mellitus Complications,Diabetes Related Complications,Diabetes-Related Complication,Diabetic Complication
D051381 Rats The common name for the genus Rattus. Rattus,Rats, Laboratory,Rats, Norway,Rattus norvegicus,Laboratory Rat,Laboratory Rats,Norway Rat,Norway Rats,Rat,Rat, Laboratory,Rat, Norway,norvegicus, Rattus
D018342 Receptors, Adrenergic, beta-1 A subclass of beta-adrenergic receptors (RECEPTORS, ADRENERGIC, BETA). The adrenergic beta-1 receptors are equally sensitive to EPINEPHRINE and NOREPINEPHRINE and bind the agonist DOBUTAMINE and the antagonist METOPROLOL with high affinity. They are found in the HEART, juxtaglomerular cells, and in the central and peripheral nervous systems. Adrenergic beta-1 Receptor,Adrenergic beta-1 Receptors,Receptors, beta-1 Adrenergic,beta-1 Adrenergic Receptors,Adrenergic Receptor, beta-1,Receptor, Adrenergic, beta-1,beta 1 Adrenergic Receptor,Adrenergic Receptor, beta 1,Adrenergic Receptors, beta-1,Adrenergic beta 1 Receptor,Adrenergic beta 1 Receptors,Receptor, Adrenergic beta-1,Receptor, beta-1 Adrenergic,Receptors, Adrenergic beta-1,Receptors, beta 1 Adrenergic,beta 1 Adrenergic Receptors,beta-1 Adrenergic Receptor,beta-1 Receptor, Adrenergic,beta-1 Receptors, Adrenergic
D018343 Receptors, Adrenergic, beta-2 A subclass of beta-adrenergic receptors (RECEPTORS, ADRENERGIC, BETA). The adrenergic beta-2 receptors are more sensitive to EPINEPHRINE than to NOREPINEPHRINE and have a high affinity for the agonist TERBUTALINE. They are widespread, with clinically important roles in SKELETAL MUSCLE; LIVER; and vascular, bronchial, gastrointestinal, and genitourinary SMOOTH MUSCLE. Adrenergic beta-2 Receptors,Receptors, beta-2 Adrenergic,beta-2 Adrenergic Receptors,Adrenergic Receptor, beta-2,Receptor, Adrenergic, beta-2,beta 2 Adrenergic Receptors,Adrenergic Receptor, beta 2,Adrenergic Receptors, beta-2,Adrenergic beta 2 Receptors,Receptor, beta-2 Adrenergic,Receptors, Adrenergic beta-2,Receptors, beta 2 Adrenergic,beta-2 Adrenergic Receptor,beta-2 Receptors, Adrenergic
D022702 Receptors, Adrenergic, beta-3 A subclass of beta-adrenergic receptors (RECEPTORS, ADRENERGIC, BETA). The beta-3 adrenergic receptors are the predominant beta-adrenergic receptor type expressed in white and brown ADIPOCYTES and are involved in modulating ENERGY METABOLISM and THERMOGENESIS. Adrenergic beta-3 Receptors,Beta 3 Adrenergic Receptor,Receptors, beta-3 Adrenergic,beta-3 Adrenergic Receptors,Adrenergic Receptors, beta-3,Adrenergic beta-3 Receptor,Receptor, Adrenergic beta-3,beta3 Adrenoreceptor,Adrenergic Receptors, beta 3,Adrenergic beta 3 Receptor,Adrenergic beta 3 Receptors,Adrenoreceptor, beta3,Receptor, Adrenergic beta 3,Receptors, Adrenergic beta-3,Receptors, beta 3 Adrenergic,beta 3 Adrenergic Receptors,beta-3 Receptor, Adrenergic,beta-3 Receptors, Adrenergic

Related Publications

V Melih Altan, and Ebru Arioglu, and Sahika Guner, and A Tanju Ozcelikay
February 2001, Journal of autonomic pharmacology,
V Melih Altan, and Ebru Arioglu, and Sahika Guner, and A Tanju Ozcelikay
September 1992, Nihon yakurigaku zasshi. Folia pharmacologica Japonica,
V Melih Altan, and Ebru Arioglu, and Sahika Guner, and A Tanju Ozcelikay
December 1985, European journal of pharmacology,
V Melih Altan, and Ebru Arioglu, and Sahika Guner, and A Tanju Ozcelikay
September 2001, Clinical science (London, England : 1979),
V Melih Altan, and Ebru Arioglu, and Sahika Guner, and A Tanju Ozcelikay
October 1987, British journal of pharmacology,
V Melih Altan, and Ebru Arioglu, and Sahika Guner, and A Tanju Ozcelikay
February 1995, Biochemical Society transactions,
V Melih Altan, and Ebru Arioglu, and Sahika Guner, and A Tanju Ozcelikay
May 1996, The Journal of the Association of Physicians of India,
V Melih Altan, and Ebru Arioglu, and Sahika Guner, and A Tanju Ozcelikay
September 1998, Nephron,
V Melih Altan, and Ebru Arioglu, and Sahika Guner, and A Tanju Ozcelikay
March 1997, Trends in pharmacological sciences,
V Melih Altan, and Ebru Arioglu, and Sahika Guner, and A Tanju Ozcelikay
December 1997, Journal of autonomic pharmacology,
Copied contents to your clipboard!